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ABSTRACT 
 
The hepatitis C virus genotype is considered to be the most important baseline 
predictor of a sustained virological response in patients with chronic hepatitis C 
treated with pegylated interferon and ribavirin. The influence of the subtype on the 5 
sustained virological response was investigated in patients infected with genotypes 1, 
4, 5 or 6. This study was done on 597 patients with chronic hepatitis C who were 
given pegylated interferon and ribavirin for 48 weeks. The overall rate of sustained 
virological response in the 597 patients was 37.8%. Univariate analysis indicated that 
the sustained virological response of patients infected with subtype 1b (39%) tended 10 
to be higher than that of patients infected with subtype 1a (30.6%; p=0.06) and it was 
similar to those patients infected with subtypes 4a (51.3%, p=0.12) or 4d (51.7%, 
p=0.16). Multivariate analysis indicated that five factors were independently 
associated with sustained virological response: the age (OR 0.97; 95% CI = 0.95-
0.99), absence of cirrhosis (OR: 2.92; 95% CI = 1.7-5.0; p<0.01), absence of HIV 15 
coinfection (OR: 2.08; 95% CI = 1.2-3.5; p<0.01), low baseline plasma HCV RNA 
concentration (OR: 1.74; 95% CI = 1.2-2.6; p<0.01) and the subtype 1b (OR: 1.61; 
95% CI = 1.0-2.5; p=0.04) or subtypes 4a and 4d (OR: 2.03; 95% CI = 1.1-3.8; 
p=0.03). In conclusion, among difficult-to-treat genotypes, the subtype 1a is 
associated with a lower response to anti-HCV therapy than subtypes 1b, 4a and 4d. 20 
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INTRODUCTION 
 
Hepatitis C virus (HCV) infection is a major health care burden worldwide. 
HCV is a single-stranded, positive-polarity RNA virus belonging to the genus 
Hepacivirus of the family Flaviviridae. The HCV genome has the following gene 5 
order: 5’-C-E1-E2-p7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-3’ and encodes a single 
long polyprotein [Lindenbach and Rice, 2005]. The sequences of the genomes of 
HCV variants differ considerably and have been divided into six genotypes. Each of 
these 6 genotypes can be further subdivided into a series of subtypes [Simmonds et 
al., 2005].  10 
 Anti-HCV therapy has progressed significantly in recent years. The standard 
and most effective initial treatment for chronic hepatitis C is a combination of 
pegylated interferon-alpha plus ribavirin [Fried et al., 2002; Manns et al., 2001]. The 
HCV genotype is considered to be the most important baseline predictor of a 
sustained virological response in patients with chronic hepatitis C. Treatment is 15 
effective in approximately 80% of patients infected with HCV genotype 2 or 3 but is 
less than 50% in those infected with HCV genotype 1 [Fried et al., 2002; Hadziyannis 
et al., 2004; Manns et al., 2001]. Genotype 4 is considered as a difficult-to-treat 
genotype [Legrand-Abravanel et al., 2005; Martin-Carbonero et al., 2008; Roulot et 
al., 2007; Zeuzem, 2004], even if high sustained virological response rates (67–70%) 20 
have been reported for patients in the Middle East infected with genotype 4 [Hasan et 
al., 2004; Kamal et al., 2005]. The sensitivity of genotypes 5 and 6 to interferon and 
ribavirin may be similar to that of genotypes 2 and 3 [Bonny et al., 2006; Fung et al., 
2008; Hui et al., 2003; Legrand-Abravanel et al., 2004]. However, treatment for 48 
weeks is still recommended for patients infected with genotypes 5 or 6.  25 
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Most commercial assays determine the genotype by analysing the 5’UTR. But 
the 5’UTR is highly conserved, which limits its use for discriminating genotype 6 from 
genotype 1 and subtypes within genotypes 1, 2, 3, 4, and 6 [Cantaloube et al., 2006; 
Chen and Weck, 2002; Sandres-Saune et al., 2003]. For example, the G residue at 
position 243 of the 5’UTR was originally considered to be representative of subtype 5 
1b, but it also occurs in a substantial proportion of subtype 1a viruses. Many studies 
have shown that the NS5B region is discriminative for determining HCV genotypes 
and their subtypes [Cantaloube et al., 2006; Sandres-Saune et al., 2003]. However, 
most clinical trials have determined the genotype by analysing the 5’UTR region, 
making it impossible to study the influence of the subtype on the virological response, 10 
especially in difficult-to-treat patients infected with HCV genotypes 1 or 4.  
An observational study was therefore carried out on a large group of patients 
to evaluate the influence of HCV subtype on the response to pegylated interferon 
plus ribavirin.  
 15 
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PATIENTS AND METHODS 
Patient selection 
A total of 14 centers in France took part in the study between January 2004 and June 
2007. Patients were selected in the present study based on the following criteria: (i) 
patients were infected with HCV-1, 4, 5 and 6 only; (ii) subjects could be naïve or not 5 
for previous interferon-based therapy; (iii) patients could be or not coinfected with 
human immunodeficiency virus (HIV) or the hepatitis B virus (HBV). The following 
data were collected: age, gender, geographical origin of the patients, source of 
transmission, and co-infection with HIV or HBV, and Metavir score of liver biopsies.  
 10 
Patient description 
Five hundred and ninety seven patients were included, 67.7% were men (Table 1). 
The mean age was 48.9 ± 11.1 years old. One hundred and ninety three (32.3%) had 
been previously treated with a standard interferon-based regimen. Fourteen patients 
were infected with HBV and 141 were also infected with HIV. Approximately one 15 
quarter of the patients (23.4%) who underwent a liver biopsy had cirrhosis. 
 
 
Treatment 
Patients were given pegylated interferon alpha-2a (Pegasys, Roche laboratories,  20 
Palo Alto, CA), 180 µg/week, or pegylated interferon alpha-2b (PEG-Intron, Schering 
Plough , Kenilworth, NJ), 1.5 µg/kg/week, at the discretion of the physician, combined 
with ribavirin (Copegus, Roche laboratories or Rebetol, Schering Plough), 1000 
mg/day if the body weight was ≤ 75 kg, or 1200 mg/day if the body weight was > 75 
kg, for 48 weeks. The doses of pegylated interferon and ribavirin were modified 25 
according to standard criteria and procedures [Dienstag and McHutchison, 2006]. 
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Patients with an undetectable HCV RNA or with a >2 log decline in HCV-RNA at 
week 12 were considered to be early virological responders and were treated for 48 
weeks. The treatment of patients with a <2 log decline at week 12 was stopped and 
they were considered to be non-responders. All patients were followed up for 24 
weeks after the end of treatment. The primary end point was undetectable serum 5 
HCV-RNA 24 weeks after treatment cessation. 
 
HCV RNA quantitation 
HCV-RNA was measured at baseline and 12 weeks after beginning the treatment 
with Versant HCV-RNA 3.0 bDNA (Siemens Healthcare Diagnostics, Tarrytown, NY) 10 
(limit of detection: 615 IU/ml), or Cobas Taqman Roche Diagnostics (Roche 
Molecular Systems, Pleasanton, CA) (limit of detection: 15 IU/ml), depending on the 
assay used routinely in each center. The plasma HCV RNA concentrations measured 
with the bDNA test were adjusted to take into account the mean difference between 
the two assays [Pittaluga et al., 2008]. Values of 0.49 log copies/ml for genotype 1a, 15 
0.45 log copies/ml for genotype 1b, and 0.26 log copies/ml for genotype 4 were 
added to plasma HCV RNA concentrations measured with the bDNA test (n=269). 
The plasma HCV RNA concentrations of patient infected with genotype 5 were not 
adjusted since the mean difference between the two assays is less than 0.05 log 
copies /ml [Sarrazin et al., 2006; Vermehren et al., 2008]. Similarly, the plasma RNA 20 
HCV concentration measured in patients infected with genotype 6 was not adjusted 
as no data are available on the quantitation for this genotype with the two assays. 
 
HCV genotyping 
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The HCV genotype was determined by sequencing a 382 nt fragment within 
the NS5B region of the HCV genome [Laperche et al., 2005; Sandres-Saune et al., 
2003]. 
 
Statistical analysis 5 
Statistical analysis was performed with the software Stata 8.0 (Stata Corporation, 
Grand Forks, ND). Non-parametric tests were used to compare the differences 
between the groups (Mann-Whitney U test for continuous variable; X² test for 
parametric variables). A p value of less than 0.05 was considered to be significant. 
Baseline predictors of the virological response were evaluated by univariate and 10 
multivariate analyses. The following covariates were analysed: type of pegylated 
interferon (pegylated interferon alpha-2a or pegylated interferon alpha-2b), previous 
interferon-based therapy, sex, age as continuous variable, geographical origin of the 
patients, liver cirrhosis (F4 score according to the METAVIR classification), HBV and 
HIV co-infection, baseline plasma HCV RNA concentration, classified as ≤ 800 000 15 
IU/ml (5.9 log IU/ml) or > 800 000 IU/ml, HCV genotype and HCV subtypes 1a, 1b, 
4a and 4d. Variables with a p value of 0.10 or less after univariate analysis were 
entered into a multivariate, backward, stepwise logistic regression analysis to identify 
significant variables associated independently with the virological response. Odds 
ratios were estimated from the model and are given with their 95% confidence 20 
intervals. Patients infected with non genotypes 1a, 1b, 4a and 4d were excluded from 
the analyses due to the low number of patients within each subtype. Since they 
presented the same early and sustained virological response, patients infected with 
subtypes 4a and 4d were grouped to increase the number of subjects.  
 25 
Page 9 of 22
John Wiley & Sons
Journal of Medical Virology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 9 
The statistical analysis was confirmed independently by Dr M Delobel-Ayoub (Inserm 
Unit 558). 
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RESULTS 
 
Genotype distribution 
The demographic and clinical characteristics of the 597 patients are 
summarized in Table 1. The HCV genotypes were 1 (n=494), 4 (n=91), 5 (n=8), and 5 
6 (n=4). The distribution of the subtypes is outlined in Table 2. Of the patients 
infected with genotype 1, 44.5% (n=220) were infected with the subtype 1a and 
51.2% (n=253) with subtype 1b. The patients infected with genotype 4 showed a 
wider range of subtypes, with more than 9 subtypes identified, although subtypes 4a 
(40.7%) and 4d (31.8%) were the main ones. 10 
 
Early virological response  
Almost two-thirds of the patients (64.1%) had a virological response, defined 
as an undetectable HCV RNA or a 2-log decline from baseline HCV RNA, by week 
12. The early virological responses for each subtype are shown in Table 2. Univariate 15 
analysis identified 6 factors that were associated with an early virological response: 
the type of pegylated interferon, previous interferon-based treatment, absence of 
cirrhosis, co-infection with HIV, low baseline HCV RNA and the genotype. Patients 
given pegylated interferon alpha 2a had a better early virological response (67.8%) 
than patients given pegylated interferon alpha 2b (54.3%, p<0.01). The early 20 
virological response of interferon-experienced patients was poorer (56%) than that of 
naive patients (69%, p<0.01). Similarly, the early virological response rate of cirrhotic 
patients was lower (48.4%) than that of non-cirrhotic patients (67.7%, p<0.01). 
Patients infected with both HIV and HCV had a lower early virological response rate 
(48.2%) than patients infected with HCV alone (69%, p<0.01). Patients with a low 25 
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baseline HCV RNA (≤ 800 000 IU/ml, or 5.9 log IU/ml) have a better early virological 
response (73.6%) than patients with a high baseline HCV RNA (> 800 000 IU/ml, or 
5.9 log IU/ml) (58.4%). Patients infected with genotype 1 or 4 had similar early 
virological responses (61.4 and 64.1%, p=0.56). Whereas, all the patients infected 
with genotypes 5 or 6 had undetectable HCV RNA by week 12. Patients infected with 5 
genotype 1a or 1b had similar early virological responses (61.4% and 64.4%, 
p=0.52), as did patients infected with genotype 4a or 4d (64.8% and 66.6%, p=0.84). 
No difference according to gender, geographical origin of the patients or HBV co-
infection was observed. Multivariate analysis indicated that five factors were 
independently associated with the early virological response: treatment with 10 
pegylated interferon alpha-2a, interferon-naive patients, absence of cirrhosis, 
absence of co-infection with HIV and low plasma HCV RNA concentration at baseline 
(≤ 5.9 log UI/mL) (Table 3). 
 
Sustained virological response 15 
The overall rate of sustained virological response was 37.8% for the 597 
patients. The rates of sustained virological response according to the subtype are 
shown in Table 2. Univariate analysis identified seven factors that were associated 
with a sustained virological response: previous interferon-based treatment, age, 
cirrhosis, co-infection with HIV, viral load before treatment, HCV genotype and HCV 20 
subtype. Patients who had previously failed to respond interferon-based therapy 
were less likely to have a sustained virological response (29%) than were naive 
patients (43%, p<0.01). The responders were younger (47.3 years) than the non-
responders (49.8 years, p<0.01). The rate of sustained virological response of 
patients without cirrhosis was 42.2%; it was only 19.1% in patients with a cirrhosis 25 
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(p<0.01). The rate of sustained virological response for HIV-HCV co-infected patients 
was lower (28.3%) than that of patients infected with HCV alone (40.7%; p<0.01). 
Patients with a low baseline HCV RNA (≤ 800 000 IU/ml) have a better sustained 
virological response (48.6%) than patients with an higher baseline HCV RNA (32.1%; 
p<0.01). The sustained virological response of patients infected with genotype 4 was 5 
significantly higher (49.4%) than that of patients infected with genotype 1 (35.4%) 
(p=0.01). Genotype 5 infected patients had a low sustained virological response rate 
(37.5%) similar to that of patients infected with genotype 1. Those patients infected 
with subtype 1a tended to have a lower sustained virological response rate (30.6%) 
than those infected with subtype 1b (39%; p=0.06), and it was lower than patients 10 
infected with genotype 4a (51.3%, p<0.01) or 4d (51.7%, p< 0.01). Patients infected 
with genotype 1b, 4a, and 4d presented the same rate of sustained virological 
response (p>0.10). Neither gender, geographical origin, nor HBV co-infection 
influenced the rate of sustained virological response. Multivariate analysis revealed 
five factors that were independently associated with a sustained virological response: 15 
the age, absence of cirrhosis, absence of HIV coinfection, low baseline plasma HCV 
RNA concentration (≤ 5.9 log UI/mL) and the subtypes 1b, 4a or 4d (Table 3). 
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DISCUSSION 
 
A large observational study of chronic hepatitis C-infected patients was 
conducted to assess the influence of virus subtype on the virological response to 
pegylated interferon and ribavirin therapy. The subtype was accurately determined by 5 
phylogenetic analyses of the NS5B region of the HCV genome. Multivariate analysis 
revealed that the subtypes 1b, 4a, and 4d were independent variable associated with 
the sustained virological response.  
Several factors influence the rate of sustained virological response to 
pegylated interferon and ribavirin therapy: pharmacological, host and virological 10 
factors [Everson et al., 2006; Fried et al., 2002; Manns et al., 2001; Nicot et al., 2008; 
Zeuzem, 2004]. In the present study, patients treated with pegylated interferon alpha-
2a had a better early virological response than patient treated with pegylated 
interferon alpha 2b. However, the type of pegylated interferon did not influence the 
sustained virological response. This is in keeping with the results of the IDEAL trial 15 
where patients treated with pegylated interferon alpha 2a and ribavirin had a better 
end-of-treatment response than patients treated with pegylated interferon alpha 2b, 
but the sustained virological responses of the two groups were similar [Sulkowski et 
al., 2008]. HIV-HCV patients show the same difference in the early virological 
responses of the patients treated with pegylated interferon alpha-2a and patients 20 
treated with pegylated interferon alpha-2b [Vispo et al., 2008].  
Patients who had failed a previous interferon-based therapy had a lower 
sustained virological response. Several trials on HCV-infected and HIV-HCV 
coinfected patients have shown that retreatment of (pegylated) interferon-
experienced patients with pegylated interferon and ribavirin combination therapy 25 
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results in a much lower sustained virological response rate than treatment of 
(pegylated) interferon-naive patients [Camma et al., 2002; Krawitt et al., 2005; 
Sherman et al., 2006]. 
In the present work, older age and cirrhosis and HIV coinfection were 
associated with a poor sustained virological response. It is well established that these 5 
host factors are independent predictors of nonresponse to interferon-based treatment 
of patients with chronic hepatitis C [Everson et al., 2006; Fried et al., 2002; Martin-
Carbonero et al., 2008; Zeuzem, 2004]. 
Baseline plasma HCV RNA concentration is a viral factor influencing the 
treatment in chronic hepatitis C in most studies [Fried et al., 2002; Manns et al., 10 
2001; McHutchison et al., 1998; Poynard et al., 1998]. Baseline plasma HCV RNA 
concentration and virological response at week 4 may now influence the treatment 
duration in genotype 1 infected patients [Ferenci et al., 2008; Yu et al., 2008; Zeuzem 
et al., 2006]. In the present work, the statistical analyses found a higher early and 
sustained virological response rate in patients with low baseline plasma HCV RNA 15 
concentration. The same result was obtained when the analyses were conducted 
without adjusting the HCV RNA concentrations for genotype 1 and 4.  
The HCV genotype is considered to be the most important baseline predictor 
of a sustained virological response in patients with chronic hepatitis C. A low 
sustained virological response rate was found for patients infected with genotype 5 20 
(37.5%), unlike previous findings for this genotype [Bonny et al., 2006; Legrand-
Abravanel et al., 2004]. The findings of these two studies were supported by 
comparison with two control groups of patients infected with genotypes 1 or 2/3. The 
discrepancy with previous work may be because genotype 5-infected patients in the 
present work were more likely to suffer from cirrhosis and were older than the other 25 
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patients in the present study. Only 4 patients were infected with genotype 6, but the 
rates of early or sustained virological response in this group of patients were very 
good, as previously described [Fung et al., 2008; Hui et al., 2003]. 
Several clinical trials have found that patients infected with genotypes 1 or 4 
are less likely to achieve a sustained virological response [Fried et al., 2002; 5 
Legrand-Abravanel et al., 2005; Manns et al., 2001; Martin-Carbonero et al., 2008; 
Roulot et al., 2007]. A previous retrospective study found that French patients 
infected with subtype 4a had a higher rate of sustained virological response (58%) 
than those infected with subtype 4d (43%, p=0.035) [Roulot et al., 2007]. A study has 
reported a group of ten HIV-positive patients who were acutely infected with HCV 10 
genotype 4d. None of the 10 patients treated early with antiviral therapy had a 
sustained virological response, suggesting that this subtype is less sensitive to 
interferon-based therapy [Serpaggi et al., 2006]. However, no difference in the 
virological responses of patients infected with subtypes 4a or 4d was found at week 
12 or 6 months after completion of the therapy. By contrast, among difficult-to-treat 15 
genotypes, patients infected with subtype 1b, 4a and 4d had a higher sustained 
virological response than those infected with subtype 1a. This was not reported 
before because most studies, including pivotal studies on pegylated interferon-alpha 
2a and pegylated interferon-alpha 2b registration, determined the HCV genotype 
using a method based on the 5’UTR region that does not discriminate accurately the 20 
subtypes [Fried et al., 2002; Manns et al., 2001]. Therefore, the influence of the 
subtype could not be determined.  
In conclusion, in patients infected with difficult-to-treat genotypes, the subtype 
1a may be considered as a pejorative factor of response to antiviral therapy. Further 
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studies are needed to identify the molecular basis of this difference and to assess the 
possibility of using the genotype 1 subtype to optimize anti-HCV therapy. 
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Table 1. Baseline characteristics of the 597 treated patients   
Characteristic Total 
(n=597) 
Genotype 1 
(n=494) 
Genotype 4 
(n=91) 
Genotype 5 
(n=8) 
Genotype 6 
(n=4) 
 
     
Gender, n (%) 
     
     Female 193 (33) 159 (32.8) 30 (33) 4 (50) 0 
     Male 404 (67) 335 (67.8) 61 (67) 4 (50) 4 (100) 
Age, mean years ± SD 48.9 ± 11.1 49.3 ± 11.2 45.2 ± 8.5 63.2 ± 8.9 59.8 ± 7.3 
Source of infection, n (%) 
     
     Blood transfusion 132 (22.1) 120 (24.3) 9 (9.9) 3 (37.5) 0 
     Drug abuse 194 (32.5) 159 (32.1) 35 (38.5) 0 0 
     Nosocomial 40 (6.7) 32 (6.5) 5 (5.5) 2 (25) 1 (25) 
     Sexual 11 (1.8) 8 (1.6) 3 (3.3) 0 0 
     Unknown 222 (37.3) 175 (35.5) 39 (42.8) 3 (37.5) 3 (75) 
 
Liver Fibrosis, n (%)* 
     
     F0-3 412 (76.6) 336 (75.2) 68 (86.1) 5 (62.5) 3 (75) 
     F4 126 (23.4) 111 (24.8) 11 (13.9) 3 (37.5) 1 (25) 
Co-infection, n (%) 
      HIV 
      HBV 
 
141(23.6) 
14 (2.3) 
 
112 (22.6) 
12 (2.4) 
 
29 (31.8) 
2 (2.2) 
 
0 
0 
 
0 
0 
Mean HCV RNA (log 
IU/mL) (± SD) 
Range HCV RNA (log 
IU/mL) 
6.10 ± 0.6 
 
3.34 - 8.29 
6.15 ± 0.6 
 
3.44 - 8.29 
5.87 ±0.6 
 
3.34 – 7.47 
 
5.80 ± 0.5 
 
5.34 – 6.83 
6.21 ±0.8 
 
5.16 - 6.89 
Previous interferon based 
therapy 
     
     Yes 193 (32.3) 172 (34.8) 20 (22) 1 (12.) 0 
     No 404 (67.7) 322 (65.3) 71 (78) 7 (87.5) 4 (100) 
Treatment 
     
   Peg-IFNα−2a + Ribavirin 436 (73.1%) 361 (73.1%) 65 (74.1%) 4 (75%) 4 (100%) 
   Peg-IFNα-2b + Ribavirin 161 (26.9%) 133 (26.9%) 26 (28.6%) 2 (25%) 0 
 
*Data were unavailable for 59 patients, including 47 in the genotype 1 group and 12 
in the genotype 4 group.  
 5 
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Table 2. Virological responses according to the genotype and subtype  
Genotype Subtype n Early virological 
response, n (%) 
Sustained 
virological 
response, n (%) 
1 all subtypes 494 310 (62.7)  175 (35.4) 
 1a 220 135 (61.4) 68 (30.6) 
 1b 253 161 (64.1) 98 (39) 
 other subtypes 21 14 (66.6) 9 (42.8) 
4 all subtypes 91 60 (65.9) 48 (52.7) 
 4a 37 24 (64.8) 19 (51.3) 
 4d 29 22 (66.6) 15 (51.7) 
 other subtypes 25 17 (68) 12 (48) 
5 5a 8 8 (100) 3 (37.5) 
6 all subtypes 4 4 (100) 3 (75) 
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Table 3: Multivariate analysis of factors associated with virological response. 
 n Odds ratio 95% CI P value 
 
Early virological response 
 
 
538 
   
Type of pegylated interferon 
Peg-IFN α2b 
Peg-IFN α2a 
 
143 
395 
 
1 
2.57 
 
 
1.7 - 3.9 
 
 
<0.01 
Previous interferon based therapy 
Yes 
No 
 
184 
354 
 
1 
1.50 
 
 
1.0 - 2.2 
 
 
0.04 
Cirrhosis 
Yes 
No 
 
126 
412 
 
1 
2.02 
 
 
1.3 - 3.1 
 
 
<0.01 
HIV coinfection  
Yes 
No 
 
124 
414 
 
1 
2.8 
 
 
1.8 - 4.4 
 
 
<0.01 
Baseline HCV RNA  
> 5.9 log IU/ml 
≤ 5.9 log IU/ml 
 
190 
348 
 
1 
2.06 
 
 
1.4 – 3.1 
 
 
<0.01 
 
Sustained virological response 
 
 
484 
   
Age  0.97 0.95-0.99 <0.01 
Cirrhosis 
Yes 
No  
 
117 
367 
 
1 
2.92 
 
 
1.7 - 5.0 
 
 
<0.01 
HIV coinfection  
Yes 
No 
 
129 
355 
 
1 
2.08 
 
 
1.2 – 3.5 
 
 
<0.01 
Baseline HCV RNA  
> 5.9 log IU/ml 
≤ 5.9 log IU/ml 
 
323 
164 
 
1 
1.74 
 
 
1.2 – 2.6 
 
 
< 0.01 
Subtypes 
1a 
1b 
4a + 4d 
 
201 
226 
57 
 
1 
1.61 
2.03 
 
 
1.0 – 2.5 
1.1 - 3.8 
0.03 
 
0.04 
0.03 
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